Please Authorize In and usage this article’s on page print button to print this article.
Property Spotlight: Riverwalk Properties
Mersana Therapeutics CEO Anna Protopapas
After much more compared to 3 years of producing a more powerful kind of drug that specifically targets cancer cells, Mersana Therapeutics strategies to start human trials along with its initial such drug this summer.
That’s in portion thanks to an expanded partnership along with Japan-based drugmaker Takeda Pharmaceutical Company which could delivering $60 million to Mersana this year, and $750 million in turning point mayments in the long run, plus royalties if the drug is approved. The brand-new agreement, announced last week, represents the 2nd expansion of one forged in between the 2 companies in 2014. Mersana CEO Anna Protopapas says that’s evidence of the potential so much of her company’s means of increasing the cancer-killing potential of a kind of drug called antibody-drug conjugates by four or 5 times.
Mersana Therapeutics CEO Anna Protopapas
“Just what you’re checking out is our early victory in the partnership that has actually brough Takeda spine to the table,” she said.
Upcoming Events
]]>
Takeda now has actually the choice to sell the drug — most likely intended for breast, gastric and/or non-little cell lung cancers — outside the US and Canada. The brand-new agreement additionally too enables Takeda to usage Mersana’s technology much more broadly. Mersana will certainly have actually the possibility to companion on among the drugs in which Takeda uses Fleximer, thereby expanding the lot of drugs Mersana has actually in development.
“At this stage, we’re focused on building out pipeline… It allows us to retain considerable value from the pipeline which leverging every little thing Takeda has actually to offer,” said Protopapas.
She said that Mersana strategies to file for permission to start clinical trials this summer, and the Firm now strategies to file one more such application in the initial half of 2017.
Mersana, which has actually 44 employees, has actually gotten 2 rounds of financing to date, one in 2012 and one in 2015, for a total of $52 million. Combined along with its partnerships along with Takeda and Merck Serono, potentially worth much more compared to $2 billion in coming years, Protopapas says she isn’t under stress to delivering the Firm public to grab access to much more financing.
“We’re constantly looking at strategies for financing, yet we are fortunate to have actually a rather tough balance piece ideal now.”
0 comments
Post a Comment